Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
ASKA’s Contraceptive, Vabysmo Label Expansion Now in Line for Japan Approval
ASKA Pharmaceutical’s contraceptive pill drospirenone cleared the review of a key health ministry panel on April 25, along with the label expansions of two products, setting the stage for Japanese regulatory approval. The Pharmaceutical Affairs Council’s First Committee on Drugs…
To read the full story
Related Article
- Japan Approves Moderna RSV Vaccine, GSK’s ADC, and More
May 20, 2025
- MHLW Panel to Discuss Approval of ASKA’s Contraceptive Pill and More on April 25
April 18, 2025
- ASKA In-Licenses Another Women’s Health Drug from Insud
December 26, 2024
- Vabysmo Filed for Label Expansion into Angioid Streaks in Japan: Chugai
September 9, 2024
REGULATORY
- Japan OKs Honebuto, Growth Strategy with Patented Drug Market Goals
July 21, 2026
- Takeda’s Oveporexton, Rhythm’s Imcivree Up for Japan Panel Review Aug. 3
July 21, 2026
- Japan’s Immunization Act Bill Set to Clear Diet after Session Extension
July 21, 2026
- Japan Eyes Early FY2027 Rollout of RSV Antibodies under NIP: Minister
July 21, 2026
- AMED-Backed R&D Yielded 31 Regulatory Approvals in FY2025
July 17, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…